Research programme: immune checkpoint antibodies - ImmuneOncia Therapeutics

Drug Profile

Research programme: immune checkpoint antibodies - ImmuneOncia Therapeutics

Alternative Names: IMC-001; STI-A1015

Latest Information Update: 08 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sorrento Therapeutics
  • Developer ImmuneOncia Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Programmed cell death-1 ligand-1inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Feb 2018 South Korean Ministry of Food and Drug Safety (MFDS) approves IND application for STI A1015 in cancer
  • 09 May 2016 ImmuneOncia Therapeutics plans phase I trial for Cancer in South Korea
  • 02 Mar 2016 Yuhan and Sorrento Therapeutics agree to co-develop and co-promote immune checkpoint inhibitors in South Korea for cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top